Download PDF
Der Klinikarzt 2019; 48(11): 469-475
DOI: 10.1055/a-1025-8278
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Management und Diagnostik von Staphylococcus-aureus-Blutstrominfektionen

Neue Entwicklungen
Sebastian Weis
1   Institut für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena
2   Center for Sepsis Control and Care (CSCC), Universitätsklinikum Jena
3   Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Jena
,
Stefan Hagel
1   Institut für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena
2   Center for Sepsis Control and Care (CSCC), Universitätsklinikum Jena
,
Mathias W. Pletz
1   Institut für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena
2   Center for Sepsis Control and Care (CSCC), Universitätsklinikum Jena
› Author Affiliations
Further Information

Publication History

Publication Date:
22 November 2019 (online)

Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Blutstrominfektionen durch Staphylococcus aureus sind schwere Infektionserkrankungen, die mit dem Risiko von sekundären Absiedlungen, Rekurrenzen und hohen Sterblichkeitsraten assoziiert sind. Bei adäquater Diagnostik und Therapie kann das Outcome wesentlich verbessert werden. Alle Patienten mit Staphylococcus-aureus-Bakteriämie sollten infektiologisch betreut werden, um die Einhaltung der Therapiestandards zu gewährleisten. Medikamente der Wahl sind Cefazolin und Flucloxacillin bei MSSA und Daptomycin (cave: nicht bei pulmonalem Fokus) und Vancomycin bei MRSA-Infektionen. Die Therapie sollte für mindestens 14 Tage intravenös erfolgen. Inwiefern eine Oralisierung bei Patienten mit unkomplizierten Bakteriämien erfolgen kann, ist derzeit Gegenstand von Studien. Erste Daten lassen drauf schließen.

 

  • Literatur

  • 1 Hagel S, Kaasch AJ, Weis S, Seifert H, Pletz MW, Rieg S. [Staphylococcus aureus Bacteraemia – an Interdisciplinary Challenge]. Anasthesiol Intensivmed Notfallmed Schmerzther 2019; 54: 206-216
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Laupland KB, Lyytikainen O, Sogaard M. et al The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study. Clin Microbiol Infect 2013; 19: 465-471
    CrossrefPubMedGoogle Scholar
  • 3 Fätkenheuer G, Walger P, Fölsch U. Public Health: Infektiologische Expertise nötig. Dtsch Arztebl 2019; 116: A-734/B-604/C-596
    PubMedGoogle Scholar
  • 4 Pletz MW, Weis S, Forstner C, Wagenlehner F. [Urosepsis]. Urologe A 2018; 57: 79-92
    CrossrefPubMedGoogle Scholar
  • 5 Lopez-Cortes LE, Del Toro MD, Galvez-Acebal J. et al Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia. Clin Infect Dis 2013; 57: 1225-1233
    CrossrefPubMedGoogle Scholar
  • 6 Vogel M, Schmitz RP, Hagel S, Pletz MW. et al Infectious disease consultation for Staphylococcus aureus bacteremia – A systematic review and meta-analysis. J Ubfect 2016; 72: 19-28
    PubMedGoogle Scholar
  • 7 Kimmig A, Weis S, Hagel S, Forstner C, Kesselmeier M, Pletz MW. [Infectious Disease Consultations in Patients with Staphylococcus Aureus Bacteraemia – a Retrospective Observational Study at Jena University Hospital]. Dtsch Med Wochenschr 2018; 143: e2
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Loubet P, Burdet C, Vindrios W. et al Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review. Clin Microbiol Infect 2018; 24: 125-132
    CrossrefPubMedGoogle Scholar
  • 9 Brook I. Inoculum effect. Rev Infect Dis 1989; 11: 361-368
    CrossrefPubMedGoogle Scholar
  • 10 Lee S, Kwon KT, Kim HI. et al Clinical implications of cefazolin inoculum effect and beta-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia. Microb Drug Resist 2014; 20: 568-574
    CrossrefPubMedGoogle Scholar
  • 11 Weis S, Kesselmeier M, Davis JS. et al Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteremia. Clin Microbiol Infect 2019; 25: 818-827
    CrossrefPubMedGoogle Scholar
  • 12 Paul M, Zemer-Wassercug N, Talker O. et al Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?. Clin Microbiol Infect 2011; 17: 1581-1586
    CrossrefPubMedGoogle Scholar
  • 13 Beganovic M, Cusumano JA, Lopes V. et al Comparative Effectiveness of Exclusive Exposure to Nafcillin or Oxacillin, Cefazolin, Piperacillin/Tazobactam, and Fluoroquinolones Among a National Cohort of Veterans With Methicillin-Susceptible Staphylococcus aureus Bloodstream Infection. Open Forum Infect Dis 2019; 6: ofz270
    CrossrefPubMedGoogle Scholar
  • 14 Habib G, Lancellotti P, Antunes MJ. et al 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36: 3075-3128
    CrossrefPubMedGoogle Scholar
  • 15 Liu C, Bayer A, Cosgrove SE. et al Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52: 285-292
    CrossrefPubMedGoogle Scholar
  • 16 Zent C, Smith P. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tuber Lung Dis 1995; 76: 109-113
    PubMedGoogle Scholar
  • 17 Polasa K, Krishnaswamy K. Effect of food on bioavailability of rifampicin. J Clin Pharmacol 1983; 23: 433-437
    CrossrefPubMedGoogle Scholar
  • 18 Thwaites GE, Scarborough M, Szubert A. et al Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 668-678
    CrossrefPubMedGoogle Scholar
  • 19 Rieg S, Joost I, Weiss V. et al Combination antimicrobial therapy in patients with Staphylococcus aureus bacteraemia – a post hoc analysis in 964 prospectively evaluated patients. Clin Microbiol Infect 2017; 23: 406 e1-e8
    CrossrefPubMedGoogle Scholar
  • 20 Stein C, Makarewicz O, Forstner C, Weis S, Hagel S, Loffler B. et al Should daptomycin-rifampin combinations for MSSA/MRSA isolates be avoided because of antagonism?. Infection 2016; 44: 499-504
    CrossrefPubMedGoogle Scholar
  • 21 Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev 2016; 29: 321-347
    CrossrefPubMedGoogle Scholar
  • 22 Zasowski EJ, Trinh TD, Claeys KC. et al Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Antimicrob Agents Chemother 2017; 61 (02) e02015-16
    PubMedGoogle Scholar
  • 23 Rieg S, Kern WV. Die nosokomiale Staphylococcus aureus-Bakteriämie. Krankenhaushygiene up2date 2011; 6: 261-274
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Weis S, Kaasch AJ, Rieg S, Loffler B, Hagel S, Forstner C. et al Staphylococcus aureus bacteremia – a distinct entity. Dtsch Med Wochenschr 2015; 140: 982-989
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Jernigan JA, Farr BM. Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis. Ann Intern Med 1993; 119: 304-311
    PubMedGoogle Scholar
  • 26 Chong YP, Moon SM, Bang KM. et al Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study. Antimicrob Agents Chemother 2013; 57: 1150-1156
    CrossrefPubMedGoogle Scholar
  • 27 Gemmell CG, Edwards DI, Fraise AP. et al Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57: 589-608
    CrossrefPubMedGoogle Scholar
  • 28 Mermel LA, Allon M, Bouza E, Craven DE. et al Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45
    CrossrefPubMedGoogle Scholar
  • 29 Kaasch AJ, Fatkenheuer G, Prinz-Langenohl R. et al Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial. Trials 2015; 16: 450
    CrossrefPubMedGoogle Scholar
  • 30 Iversen K, Ihlemann N, Gill SU. et al Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med 2019; 380: 415-424
    CrossrefPubMedGoogle Scholar
  • 31 Willekens R, Puig-Asensio M, Ruiz-Camps I. et al Early oral switch to linezolid for low-risk patients with Staphylococcus aureus bloodstream infections: a propensity-matched cohort study. Clin Infect Dis 2018
    PubMedGoogle Scholar
  • 32 Gath J, Charles B, Sampson J, Smithurst B. Pharmacokinetics and bioavailability of flucloxacillin in elderly hospitalized patients. J Clin Pharmacol 1995; 35: 31-36
    CrossrefPubMedGoogle Scholar
  • 33 Braun P, Tillotson JR, Wilcox C, Finland M. Cephalexin and cephaloglycin activity in vitro and absorption and urinary excretion of single oral doses in normal young adults. Appl Microbiol 1968; 16: 1684-1694
    CrossrefPubMedGoogle Scholar
  • 34 Chambers J, Sandoe J, Ray S. et al The infective endocarditis team: recommendations from an international working group. Heart 2014; 100: 524-527
    CrossrefPubMedGoogle Scholar
  • 35 Divisi D, Di Tommaso S, Di Leonardo G. et al 18-fluorine fluorodeoxyglucose positron emission tomography with computerized tomography versus computerized tomography alone for the management of solitary lung nodules with diameters inferior to 1.5 cm. Thorac Cardiovasc Surg 2010; 58: 422-426
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Brondserud MB, Pedersen C, Rosenvinge FS. et al Clinical value of FDG-PET/CT in bacteremia of unknown origin with catalase-negative gram-positive cocci or Staphylococcus aureus. Eur J Nucl Med Mol Imaging 2019; 46: 1351-1358
    CrossrefPubMedGoogle Scholar
  • 37 Berrevoets MAH, Kouijzer IJE, Aarntzen E. et al (18)F-FDG PET/CT Optimizes Treatment in Staphylococcus Aureus Bacteremia and Is Associated with Reduced Mortality. J Nucl Med 2017; 58: 1504-1510
    CrossrefPubMedGoogle Scholar
  • 38 Ulmer M. GOÄ-Ratgeber: Abrechnung von kombinierten PET-/CT-Untersuchungen. Dtsch Arztebl International 2018; 115: A-2140
    PubMedGoogle Scholar
  • 39 Tseng JR, Chen KY, Lee MH. et al Potential usefulness of FDG PET/CT in patients with sepsis of unknown origin. PLoS One 2013; 8: e66132
    CrossrefPubMedGoogle Scholar
  • 40 Hagel S, Weis S, Pletz MW. SOP Management der Staphylococcus-aureus-Blutstrominfektion. Intensivmedizin up2date 2018; 14: 361-366
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Tubiana S, Duval X, Alla F. et al The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with Staphylococcus aureus bacteremia. J Infect 2016; 72: 544-553
    CrossrefPubMedGoogle Scholar
  • 42 Rybak MJ, Lomaestro BM, Rotschafer JC. et al Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: 325-327
    CrossrefPubMedGoogle Scholar